Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview of AngioDynamics
Founded in 1988 and headquartered in Queensbury, New York, AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices designed to enhance patient care through minimally invasive treatments. The company serves healthcare professionals, including interventional radiologists, nephrologists, and surgeons, by offering advanced solutions for treating cancer, peripheral vascular diseases, and other critical health conditions. AngioDynamics operates within the high-growth medical technology sector, focusing on improving patient outcomes and addressing complex medical challenges.
Core Business and Product Portfolio
AngioDynamics designs, manufactures, and markets a diverse range of medical devices across several key categories:
- Oncology Solutions: Technologies such as the NanoKnife® System and radiofrequency ablation devices enable precise, minimally invasive treatment of tumors, offering patients less invasive alternatives to traditional surgical procedures.
- Vascular Access and Peripheral Vascular Devices: Products include angiographic accessories, angioplasty devices, thrombolytic products, and venous solutions, which are critical for managing vascular health and ensuring effective blood flow.
- Dialysis and Drainage Products: These devices support nephrologists and other healthcare providers in managing kidney-related conditions and fluid drainage requirements.
The company’s commitment to innovation is evident in its focus on developing next-generation technologies that meet the evolving needs of healthcare providers and patients. By prioritizing research and development, AngioDynamics has built a robust portfolio that addresses both diagnostic and therapeutic applications.
Market Position and Competitive Landscape
AngioDynamics operates in a competitive and technologically advanced industry alongside major players such as Medtronic, Boston Scientific, and Abbott. The company differentiates itself through its focus on niche technologies like the NanoKnife® System, which offers a unique approach to cancer treatment by utilizing irreversible electroporation. Additionally, its emphasis on minimally invasive solutions aligns with the broader healthcare trend toward reducing recovery times and improving patient experiences.
While AngioDynamics derives a significant portion of its revenue from the U.S. market, it also seeks to expand its global footprint. Challenges include navigating regulatory environments, maintaining a steady innovation pipeline, and addressing pricing pressures in the healthcare sector.
Commitment to Patient Outcomes and Innovation
AngioDynamics is dedicated to advancing medical care by delivering technologies that improve clinical outcomes. Its minimally invasive devices not only enhance procedural efficiency but also reduce patient recovery times, making them an essential part of modern healthcare practices. The company’s forward-looking strategy involves continuous innovation to address unmet medical needs and adapt to changing industry dynamics.
Conclusion
With a strong focus on innovation, a diverse product portfolio, and a commitment to improving patient outcomes, AngioDynamics is well-positioned in the medical technology space. By addressing critical health challenges through minimally invasive solutions, the company continues to play a vital role in advancing healthcare practices worldwide.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 of fiscal year 2023 on
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced participation in three investor conferences in March 2023. The Raymond James Institutional Investors Conference will be held on
AngioDynamics (ANGO) reported a strong Q2 FY2023, with net sales of $85.4 million, a 9.1% increase year-over-year. Med Tech sales surged 29.7% to $24.5 million, driven by Auryon and NanoKnife products. However, the company posted a GAAP loss per share of $0.21, unchanged from the prior year. Gross margin increased to 52.8%, despite macroeconomic pressures like labor shortages. For H1 FY2023, net sales rose 7.5% to $167 million. AngioDynamics reaffirmed its FY2023 guidance for net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. This presentation focuses on AngioDynamics' commitment to transforming medical technology aimed at restoring vascular health and enhancing cancer treatment options. A live webcast will be available on the company's website, with a replay following the event.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its financial results for Q2 of fiscal year 2023 on January 5, 2023, before the market opens. A conference call with management will be held at 8:00 a.m. ET to discuss these results. Investors can participate by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and using the passcode 13734978. The call will also be webcast on the AngioDynamics website, with a replay available shortly after the call concludes.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced that President & CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on November 30, 2022. The presentation will focus on the company's mission to enhance cancer treatment and restore healthy blood flow. Interested parties can access the live webcast through the Investors section of AngioDynamics' website, with a replay available post-event.
AngioDynamics (NASDAQ: ANGO) announced the enrollment of the first patient in the APEX-AV Study, evaluating the AlphaVac MMA F1885 System for treating acute intermediate-risk pulmonary embolism (PE). Conducted at 20 U.S. hospital sites, the study aims to assess the device's efficacy and safety. Key endpoints include RV/LV ratio reduction and the rate of major adverse events within 48 hours. This trial, in partnership with The PERT Consortium and Viz.ai, aims to improve PE care using advanced AI recruitment strategies.
AngioDynamics, a medical technology company, reported net sales of $81.5 million for the first quarter of fiscal 2023, marking a 5.9% increase from the prior year. Med Tech sales rose by 29.6% to $22.8 million, driven by solid performances from the Auryon and thrombectomy platforms. However, Med Device sales declined by 1.1% to $58.7 million. The company experienced a gross margin decrease to 51.9% and reported a net loss of $13.0 million or $0.33 per share. Fiscal year 2023 guidance is reaffirmed, expecting net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its first quarter fiscal year 2023 financial results on October 6, 2022, before market open. Management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Investors can join the conference call by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international), using passcode 13732702. The call will be webcast on AngioDynamics' website, with a replay available shortly after the call.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Executive Vice President and CFO, Stephen Trowbridge, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast of the presentation on AngioDynamics' website, with a replay available afterward. The company focuses on innovative medical technologies aimed at restoring blood flow, enhancing cancer treatment options, and improving patient quality of life. More information is available at www.angiodynamics.com.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
What is the NanoKnife® System?
Who are AngioDynamics' primary customers?
How does AngioDynamics differentiate itself from competitors?
What challenges does AngioDynamics face in its industry?
What is AngioDynamics' approach to innovation?
Where does AngioDynamics generate most of its revenue?
What role does AngioDynamics play in the healthcare industry?
